AMG 337 is a selective inhibitor of the MET receptor tyrosine kinase, which plays a key role in tumor growth and metastasis. It is primarily investigated for its potential in treating cancers that exhibit dysregulation of the MET signaling pathway, such as certain types of gastric, lung, and esophageal cancers. By blocking MET activation, AMG 337 helps suppress cancer cell proliferation, survival, and invasion. It has shown particular promise in tumors with MET gene amplification, where it can induce tumor regression in preclinical models. Due to its targeted mechanism, AMG 337 is being studied in clinical trials to evaluate its efficacy and safety as a precision oncology therapy, especially in patients with advanced solid tumors who have limited treatment options.